ArticleThe Prostate2026
The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevious studies have demonstrated an association between PSMA-PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA-PET SUVmax and rPFS in patients with mHSPC.
methodsThe optimal SUVmax cut-off for rPFS was determined using Harrell's C-index. Baseline characteristics were compared using the χ² test between the groups and survival analyses for rPFS were performed.
resultsData from 165 patients were retrospectively analyzed, with a median follow-up of 44 months (mo) (range: 9-103 mo). A total of 17.16 was identified as the optimal SUVmax cutoff. Baseline characteristics were compared whit this threshold. SUVmax higher patients showed poor ECOG PS, high denovo metastases, high volume, higher ALP, and high median PSA level. The median rPFS for the entire cohort was 34.3 mo (95% CI: 22.0-46.5 mo). In univariate analysis, patients with higher SUVmax had a median rPFS of 23 mo versus 60.4 mo in those with low SUVmax (p < 0.001). ALP normal versus higher (41.5 vs. 20.7 mo, p = 0.011), hemoglobin < 12 g/dL versus ≥ 12 g/dL (21.2 vs. 48.4 mo, p = 0.004), low versus high tumor volume (60.4 vs. 23 mo, p = 0.004) and PSA ≥ 35 ng/mL versus PSA < 35 ng/mL (23.9 mo vs NR, p = 0.030). Furthermore, patients not receiving ARPIs therapy exhibited inferior rPFS (ADT-alone:20.7 mo vs. ADT + docetaxel:19.2 mo vs. ADT plus ARPIs: 48.4 mo, p = 0.002).
conclusionWe demonstrated that high SUVmax has a negative prognostic impact on rPFS in mHSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.